Again from Memorial Sloan Kettering Cancer Center, as reported in the Urology Times newspaper, androgen ablation was reported at the American Urology Association meeting this year to impair concentration, spatial ability, multitasking and other cognitive capacities. The researchers suggest patients be advised of this effect, and further study, including brain imaging, be pursued. The study was published in the July 28 online edition of the journal Cancer.

Earlier this year an increased risk of cardiovascular events was associated with Hormone Therapy.

From Duke University as presented at the American Urology Association meeting this year, and reported in Renal and Urology News:

Dr. Lionel L Banez’ group found that for every 1 mg/dl rise in total cholesterol or LDL cholesterol, the risk for recurrence after radical prostatectomy rose 1%. Men with total cholesterol levels of >217 had a 2.5 times higher risk for biochemical recurrence (PSA) than men with cholesterol <167. Statins may be investigated as possible agents in the treatment of prostate cancer.

The Memorial Sloan Kettering (MSK) Cancer Medical Center is one of the top 3 cancer hospitals in the country. A review of their radical prostatectomy results sought to determine how often they achieved the optimal results of: 1. cancer cure (per PSA)
2. full continence
3. no erectile dysfunction (need Viagra or equivalent only)

This “Trifecta” happened at: 1 year—30%
2 years–42%
3 years–47%
4 years–53%

These are the numbers for T1C and T2A cancers.

Aranchuk, et al., J Clin Onc, 23:18, 4146-51.

Be careful when getting overly optimistic quotes from local surgeons regarding their results.